Michael Houghton

Michael Houghton
Houghton in 2017
Michael Houghton
Born	1949
Birthplace	United Kingdom
Nationality	British, Canadian
Occupation	Virologist, academic
Title	Canada Excellence Research Chair in Virology; Li Ka Shing Professor of Virology; Director, Li Ka Shing Applied Virology Institute
Employer	University of Alberta
Known for	Co-discovery of Hepatitis C virus, co-discovery of Hepatitis D genome
Education	King's College London (PhD, 1977) University of East Anglia (BSc)
Awards	Nobel Prize in Physiology or Medicine (2020) Albert Lasker Award for Clinical Medical Research (2000) Robert Koch Prize (1993)

Sir Michael Houghton (born 1949) is a British-born virologist and Nobel Prize laureate whose work fundamentally changed the landscape of global public health. Together with colleagues Qui-Lim Choo, George Kuo, and Daniel W. Bradley, Houghton co-discovered the Hepatitis C virus (HCV) in 1989, ending a years-long search for the mysterious pathogen responsible for most cases of non-A, non-B hepatitis transmitted through blood transfusions. He also co-discovered the Hepatitis D genome in 1986. The identification of HCV led to the rapid development of diagnostic reagents to detect the virus in blood supplies, reducing the risk of acquiring HCV through blood transfusion from approximately one in three to about one in two million. It is estimated that antibody screening enabled by this discovery has prevented at least 40,000 new infections per year in the United States alone, and many more worldwide. In 2020, Houghton was awarded the Nobel Prize in Physiology or Medicine jointly with Harvey J. Alter and Charles M. Rice for the discovery of the Hepatitis C virus. He holds the positions of Canada Excellence Research Chair in Virology and Li Ka Shing Professor of Virology at the University of Alberta, where he also serves as director of the Li Ka Shing Applied Virology Institute.

Early Life

Michael Houghton was born in 1949 in the United Kingdom. Details of his childhood and family background have not been widely documented in public sources. What is known is that Houghton developed an interest in the biological sciences during his formative years, which led him to pursue higher education in the field. He grew up during a period in which molecular biology was undergoing rapid transformation, with new techniques in genetic analysis and virology emerging that would later prove central to his own career.

Houghton's early academic inclinations drew him toward the study of microbiology and virology, disciplines that were becoming increasingly important in understanding infectious diseases. The post-war expansion of British universities and investment in biomedical research created an environment in which young scientists could pursue ambitious research programmes, and Houghton took advantage of these opportunities to build the foundations of what would become a groundbreaking career in viral discovery.

Education

Houghton completed his undergraduate studies at the University of East Anglia (UEA), where he earned a Bachelor of Science degree. He then went on to pursue doctoral studies at King's College London, where he worked under the supervision of Norman Carey and James Chesterton. His doctoral thesis, titled RNA Polymerases and Transcription in the Chicken Oviduct, was completed in 1977 and focused on the molecular mechanisms of gene transcription. This training in molecular biology and the analysis of nucleic acids provided Houghton with the technical expertise that would later prove essential in his efforts to identify novel viral genomes, particularly the elusive agent responsible for non-A, non-B hepatitis.

Career

Early Research and the Search for Non-A, Non-B Hepatitis

Following the completion of his PhD, Houghton entered the field of virology research during a period in which hepatitis was a major global health concern. By the 1970s, scientists had identified the hepatitis A virus (HAV) and hepatitis B virus (HBV), but a significant proportion of transfusion-associated hepatitis cases could not be attributed to either of these agents. This mysterious illness was referred to as "non-A, non-B hepatitis" and represented a serious threat to the safety of blood supplies worldwide. The causative agent proved exceptionally difficult to identify using conventional virological methods, as the virus existed in very low concentrations in the blood and could not be grown reliably in cell culture. He also serves as director of the Li Ka Shing Applied Virology Institute at the university. Houghton's refusal was seen as a principled stand on behalf of his collaborators and highlighted ongoing debates within the scientific community about how credit for collaborative discoveries is assigned.

Personal Life

Houghton has maintained a relatively private personal life and has not made extensive public disclosures regarding his family or personal affairs. He holds both British and Canadian connections through his work at the University of Alberta. Houghton has been described as a dedicated researcher who has spent decades pursuing the goal of developing a vaccine against Hepatitis C. He was knighted for his contributions to science, bearing the honorific "Sir."

After being awarded the Nobel Prize in 2020, Houghton publicly credited his collaborators Qui-Lim Choo and George Kuo for their roles in the discovery of HCV, consistent with his earlier decision to decline the Gairdner Award on the grounds that they had not been included.

Recognition

Michael Houghton has received numerous awards and honours over the course of his career in recognition of his contributions to virology and public health.

Nobel Prize

On 5 October 2020, the Nobel Assembly at the Karolinska Institutet announced that Houghton had been awarded the Nobel Prize in Physiology or Medicine jointly with Harvey J. Alter and Charles M. Rice "for the discovery of Hepatitis C virus." The Nobel Committee noted that the discovery was of "decisive importance in the fight against blood-borne hepatitis" and that the identification of the virus made possible blood tests and new medicines that had saved millions of lives.

Other Awards

Prior to the Nobel Prize, Houghton received a number of other significant awards, including:

• The Robert Koch Prize (1993), awarded by the Robert Koch Foundation in Germany for outstanding achievements in biomedical sciences.
• The Albert Lasker Award for Clinical Medical Research (2000), one of the most prestigious awards in American medicine, shared with Harvey J. Alter for the discovery of the virus that causes Hepatitis C.
• The William Beaumont Prize in Gastroenterology, awarded by the American Gastroenterological Association.
• Recognition from the AABB (formerly the American Association of Blood Banks) for contributions to transfusion medicine.
• A Hep-DART Award for achievement in hepatitis research.

In 2019, Houghton received an honorary degree from his undergraduate alma mater, the University of East Anglia.

Legacy

The discovery of the Hepatitis C virus is considered one of the landmark achievements in 20th-century medicine and public health. Before HCV was identified, blood transfusion carried a substantial risk of transmitting a chronic, potentially fatal liver infection. The work of Houghton and his colleagues transformed transfusion medicine by enabling the development of screening tests that have effectively eliminated HCV from blood supplies in developed nations. The Nobel Committee noted that the discovery of HCV "revealed the cause of the remaining cases of chronic hepatitis and made possible blood tests and new medicines that have saved millions of lives."

Beyond diagnostic testing, the identification of HCV opened the door to the development of direct-acting antiviral agents that can cure the vast majority of chronic HCV infections. These drugs, which target specific proteins encoded by the HCV genome, represent one of the most successful examples of rational drug design in the history of infectious disease medicine. However, Houghton and others have emphasised that a vaccine will be necessary to achieve the goal of global HCV elimination, as treatment alone cannot reach the millions of undiagnosed and untreated individuals, particularly in low- and middle-income countries.

Houghton's decision to decline the Gairdner Award in 2013 because his collaborators Qui-Lim Choo and George Kuo were not included also drew attention to the question of how scientific credit is allocated for collaborative discoveries, a topic of ongoing discussion within the research community.

At the University of Alberta, Houghton has built a research programme focused on developing an HCV vaccine, continuing the translational mission that has characterised his career. His appointment as Canada Excellence Research Chair in Virology underscored Canada's investment in virology research and the university's commitment to addressing global infectious disease challenges.

Related biographies

• Paul Nurse — Geneticist
• Charles Rice — Virologist
• Don Iveson — Politician
• Peter Higgs — Theoretical Physicist
• Kazuo Ishiguro — Novelist
• Petr Pavel — Politician